Do analysts rate PRFX or DRMA?

Dermata Therapeutics has a consensus price target of $10.00, indicating a potential upside of 646.27%. Given Dermata Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Dermata Therapeutics is more favorable than PainReform. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score PainReform 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Dermata Therapeutics 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Is PRFX or DRMA more profitable?

PainReform's return on equity of 0.00% beat Dermata Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets PainReform N/A N/A N/A Dermata Therapeutics N/A -127.91% -105.05%

Do analysts recommend ENVB or PRFX?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Enveric Biosciences 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 PainReform 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Is ENVB or PRFX more profitable?

PainReform's return on equity of 0.00% beat Enveric Biosciences' return on equity. Company Net Margins Return on Equity Return on Assets Enveric Biosciences N/A -220.97% -177.47% PainReform N/A N/A N/A

Do analysts prefer PRFX or GOVX?

GeoVax Labs has a consensus target price of $150.00, indicating a potential upside of 12,505.04%. Given GeoVax Labs' stronger consensus rating and higher probable upside, analysts plainly believe GeoVax Labs is more favorable than PainReform. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score PainReform 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 GeoVax Labs 1 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.50

Is PRFX or GOVX more profitable?

PainReform's return on equity of 0.00% beat GeoVax Labs' return on equity. Company Net Margins Return on Equity Return on Assets PainReform N/A N/A N/A GeoVax Labs N/A -709.52% -399.33%

Do analysts rate RDHL or PRFX?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Redhill Biopharma 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 PainReform 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has higher valuation & earnings, RDHL or PRFX?

Redhill Biopharma has higher revenue and earnings than PainReform. PainReform is trading at a lower price-to-earnings ratio than Redhill Biopharma, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Redhill Biopharma $290K 14.54 -$430K $1.05 thousand 0.00 PainReform $20K 59.16 -$5.02M -$736.66 N/A

Is RDHL or PRFX more profitable?

Company Net Margins Return on Equity Return on Assets Redhill Biopharma N/A N/A N/A PainReform N/A N/A N/A

Do analysts rate RNAZ or PRFX?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score TransCode Therapeutics 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 PainReform 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Is RNAZ or PRFX more profitable?

PainReform's return on equity of 0.00% beat TransCode Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets TransCode Therapeutics N/A -875.35% -50.36% PainReform N/A N/A N/A

PainReform (PRFX) Competitors

$1.36 0.00 (0.00%)

Closing price 07/2/2026 04:00 PM Eastern

Extended Trading

$1.38 +0.01 (+1.10%)

As of 07/2/2026 07:58 PM Eastern

Compare

PRFX vs. DRMA, ENVB, GOVX, RDHL, and RNAZ

Should you buy PainReform stock or one of its competitors? MarketBeat compares PainReform with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with PainReform include Dermata Therapeutics (DRMA), Enveric Biosciences (ENVB), GeoVax Labs (GOVX), Redhill Biopharma (RDHL), and TransCode Therapeutics (RNAZ). These companies are all part of the "pharmaceutical products" industry.

How does PainReform compare to Dermata Therapeutics?

PainReform (NASDAQ:PRFX) and Dermata Therapeutics (NASDAQ:DRMA) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their risk, earnings, valuation, institutional ownership, media sentiment, analyst recommendations, dividends and profitability.

PainReform has higher revenue and earnings than Dermata Therapeutics. Dermata Therapeutics is trading at a lower price-to-earnings ratio than PainReform, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
PainReform	$20K	59.16	-$5.02M	-$736.66	N/A
Dermata Therapeutics	N/A	N/A	-$7.56M	-$5.31	N/A

PainReform's return on equity of 0.00% beat Dermata Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
PainReform	N/A	N/A	N/A
Dermata Therapeutics	N/A	-127.91%	-105.05%

37.3% of PainReform shares are held by institutional investors. Comparatively, 8.7% of Dermata Therapeutics shares are held by institutional investors. 34.4% of PainReform shares are held by company insiders. Comparatively, 21.9% of Dermata Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

In the previous week, PainReform's average media sentiment score of 0.00 equaled Dermata Therapeutics'average media sentiment score.

Company	Overall Sentiment
PainReform	Neutral
Dermata Therapeutics	Neutral

Dermata Therapeutics has a consensus price target of $10.00, indicating a potential upside of 646.27%. Given Dermata Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Dermata Therapeutics is more favorable than PainReform.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
PainReform	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Dermata Therapeutics	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

PainReform has a beta of 1.05, suggesting that its stock price is 5% more volatile than the broader market. Comparatively, Dermata Therapeutics has a beta of 0.67, suggesting that its stock price is 33% less volatile than the broader market.

Summary

PainReform beats Dermata Therapeutics on 8 of the 12 factors compared between the two stocks.

How does PainReform compare to Enveric Biosciences?

Enveric Biosciences (NASDAQ:ENVB) and PainReform (NASDAQ:PRFX) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, media sentiment, risk, profitability, analyst recommendations, valuation, earnings and dividends.

In the previous week, PainReform's average media sentiment score of 0.00 beat Enveric Biosciences' score of -0.35 indicating that PainReform is being referred to more favorably in the news media.

Company	Overall Sentiment
Enveric Biosciences	Neutral
PainReform	Neutral

Enveric Biosciences has a beta of 1.15, indicating that its stock price is 15% more volatile than the broader market. Comparatively, PainReform has a beta of 1.05, indicating that its stock price is 5% more volatile than the broader market.

PainReform has higher revenue and earnings than Enveric Biosciences. Enveric Biosciences is trading at a lower price-to-earnings ratio than PainReform, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Enveric Biosciences	N/A	N/A	-$8.77M	-$23.54	N/A
PainReform	$20K	59.16	-$5.02M	-$736.66	N/A

13.8% of Enveric Biosciences shares are owned by institutional investors. Comparatively, 37.3% of PainReform shares are owned by institutional investors. 2.4% of Enveric Biosciences shares are owned by insiders. Comparatively, 34.4% of PainReform shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Enveric Biosciences	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
PainReform	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

PainReform's return on equity of 0.00% beat Enveric Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Enveric Biosciences	N/A	-220.97%	-177.47%
PainReform	N/A	N/A	N/A

Summary

PainReform beats Enveric Biosciences on 8 of the 10 factors compared between the two stocks.

How does PainReform compare to GeoVax Labs?

PainReform (NASDAQ:PRFX) and GeoVax Labs (NASDAQ:GOVX) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their profitability, dividends, analyst recommendations, institutional ownership, valuation, risk, earnings and media sentiment.

PainReform has higher earnings, but lower revenue than GeoVax Labs. GeoVax Labs is trading at a lower price-to-earnings ratio than PainReform, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
PainReform	$20K	59.16	-$5.02M	-$736.66	N/A
GeoVax Labs	$2.49M	1.66	-$21.47M	-$19.12	N/A

PainReform's return on equity of 0.00% beat GeoVax Labs' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
PainReform	N/A	N/A	N/A
GeoVax Labs	N/A	-709.52%	-399.33%

In the previous week, GeoVax Labs had 2 more articles in the media than PainReform. MarketBeat recorded 2 mentions for GeoVax Labs and 0 mentions for PainReform. GeoVax Labs' average media sentiment score of 0.49 beat PainReform's score of 0.00 indicating that GeoVax Labs is being referred to more favorably in the news media.

Company	Overall Sentiment
PainReform	Neutral
GeoVax Labs	Neutral

37.3% of PainReform shares are held by institutional investors. Comparatively, 6.1% of GeoVax Labs shares are held by institutional investors. 34.4% of PainReform shares are held by company insiders. Comparatively, 0.7% of GeoVax Labs shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

PainReform has a beta of 1.05, meaning that its share price is 5% more volatile than the broader market. Comparatively, GeoVax Labs has a beta of 3.68, meaning that its share price is 268% more volatile than the broader market.

GeoVax Labs has a consensus target price of $150.00, indicating a potential upside of 12,505.04%. Given GeoVax Labs' stronger consensus rating and higher probable upside, analysts plainly believe GeoVax Labs is more favorable than PainReform.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
PainReform	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
GeoVax Labs	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50

Summary

PainReform and GeoVax Labs tied by winning 7 of the 14 factors compared between the two stocks.

How does PainReform compare to Redhill Biopharma?

Redhill Biopharma (NASDAQ:RDHL) and PainReform (NASDAQ:PRFX) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their analyst recommendations, media sentiment, earnings, dividends, risk, institutional ownership, profitability and valuation.

In the previous week, Redhill Biopharma's average media sentiment score of 0.00 equaled PainReform'saverage media sentiment score.

Company	Overall Sentiment
Redhill Biopharma	Neutral
PainReform	Neutral

7.2% of Redhill Biopharma shares are owned by institutional investors. Comparatively, 37.3% of PainReform shares are owned by institutional investors. 6.8% of Redhill Biopharma shares are owned by insiders. Comparatively, 34.4% of PainReform shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Redhill Biopharma has a beta of 4.98, indicating that its stock price is 398% more volatile than the broader market. Comparatively, PainReform has a beta of 1.05, indicating that its stock price is 5% more volatile than the broader market.

Redhill Biopharma has higher revenue and earnings than PainReform. PainReform is trading at a lower price-to-earnings ratio than Redhill Biopharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Redhill Biopharma	$290K	14.54	-$430K	$1.05 thousand	0.00
PainReform	$20K	59.16	-$5.02M	-$736.66	N/A

Company	Net Margins	Return on Equity	Return on Assets
Redhill Biopharma	N/A	N/A	N/A
PainReform	N/A	N/A	N/A

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Redhill Biopharma	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
PainReform	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Summary

Redhill Biopharma beats PainReform on 5 of the 8 factors compared between the two stocks.

How does PainReform compare to TransCode Therapeutics?

TransCode Therapeutics (NASDAQ:RNAZ) and PainReform (NASDAQ:PRFX) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their institutional ownership, valuation, earnings, media sentiment, analyst recommendations, profitability, risk and dividends.

37.3% of PainReform shares are owned by institutional investors. 0.1% of TransCode Therapeutics shares are owned by insiders. Comparatively, 34.4% of PainReform shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
TransCode Therapeutics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
PainReform	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

PainReform has higher revenue and earnings than TransCode Therapeutics. TransCode Therapeutics is trading at a lower price-to-earnings ratio than PainReform, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
TransCode Therapeutics	N/A	N/A	-$34.66M	-$50.33	N/A
PainReform	$20K	59.16	-$5.02M	-$736.66	N/A

PainReform's return on equity of 0.00% beat TransCode Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
TransCode Therapeutics	N/A	-875.35%	-50.36%
PainReform	N/A	N/A	N/A

In the previous week, TransCode Therapeutics had 1 more articles in the media than PainReform. MarketBeat recorded 1 mentions for TransCode Therapeutics and 0 mentions for PainReform. TransCode Therapeutics' average media sentiment score of 0.00 equaled PainReform'saverage media sentiment score.

Company	Overall Sentiment
TransCode Therapeutics	Neutral
PainReform	Neutral

TransCode Therapeutics has a beta of 1.23, meaning that its stock price is 23% more volatile than the broader market. Comparatively, PainReform has a beta of 1.05, meaning that its stock price is 5% more volatile than the broader market.

Summary

PainReform beats TransCode Therapeutics on 7 of the 10 factors compared between the two stocks.

Get PainReform News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding PRFX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

PRFX vs. The Competition

Export

Metric	PainReform	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$1.18M	$3.10B	$7.16B	$12.48B
Dividend Yield	N/A	2.05%	2.66%	6.52%
P/E Ratio	0.00	20.06	28.02	24.70
Price / Sales	59.16	360.33	540.37	99.49
Price / Cash	N/A	57.49	49.26	57.09
Price / Book	0.06	4.32	10.96	6.46
Net Income	-$5.02M	$64.45M	$3.57B	$337.01M
7 Day Performance	-9.93%	2.97%	2.12%	1.69%
1 Month Performance	-14.47%	6.83%	5.25%	3.81%
1 Year Performance	-81.03%	29.07%	33.29%	23.90%

PainReform Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
PRFX PainReform	0.6855 of 5 stars	$1.36 flat	N/A	-81.0%	$1.18M	$20K	N/A	4
DRMA Dermata Therapeutics	2.6185 of 5 stars	$1.21 -1.6%	$10.00 +726.4%	-79.9%	$4.87M	N/A	N/A	8	Positive News
ENVB Enveric Biosciences	0.5205 of 5 stars	$1.31 -3.0%	N/A	-90.4%	$4.82M	N/A	N/A	20	Short Interest Increase Gap Up
GOVX GeoVax Labs	2.6784 of 5 stars	$1.38 +7.0%	$150.00 +10,769.6%	-90.1%	$4.79M	$2.49M	N/A	10
RDHL Redhill Biopharma	1.3312 of 5 stars	$0.91 -1.8%	N/A	-59.7%	$4.72M	$286K	0.00	210	Short Interest Decrease Gap Down

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:PRFX) was last updated on 7/5/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

PainReform (PRFX) Competitors

PRFX vs. DRMA, ENVB, GOVX, RDHL, and RNAZ

How does PainReform compare to Dermata Therapeutics?

Summary

How does PainReform compare to Enveric Biosciences?

Summary

How does PainReform compare to GeoVax Labs?

Summary

How does PainReform compare to Redhill Biopharma?

Summary

How does PainReform compare to TransCode Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PRFX vs. The Competition

PainReform Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

PainReform (PRFX) Competitors

PRFX vs. DRMA, ENVB, GOVX, RDHL, and RNAZ

How does PainReform compare to Dermata Therapeutics?

Which has stronger valuation and earnings, PRFX or DRMA?

Is PRFX or DRMA more profitable?

Do institutionals & insiders have more ownership in PRFX or DRMA?

Does the media favor PRFX or DRMA?

Do analysts rate PRFX or DRMA?

Which has more volatility and risk, PRFX or DRMA?

Summary

How does PainReform compare to Enveric Biosciences?

Does the media refer more to ENVB or PRFX?

Which has more volatility and risk, ENVB or PRFX?

Which has higher earnings and valuation, ENVB or PRFX?

Do insiders & institutionals have more ownership in ENVB or PRFX?

Do analysts recommend ENVB or PRFX?

Is ENVB or PRFX more profitable?

Summary

How does PainReform compare to GeoVax Labs?

Which has better valuation and earnings, PRFX or GOVX?

Is PRFX or GOVX more profitable?

Does the media prefer PRFX or GOVX?

Do insiders and institutionals believe in PRFX or GOVX?

Which has more risk & volatility, PRFX or GOVX?

Do analysts prefer PRFX or GOVX?

Summary

How does PainReform compare to Redhill Biopharma?

Does the media prefer RDHL or PRFX?

Do insiders & institutionals believe in RDHL or PRFX?

Which has more risk & volatility, RDHL or PRFX?

Which has higher valuation & earnings, RDHL or PRFX?

Is RDHL or PRFX more profitable?

Do analysts rate RDHL or PRFX?

Summary

How does PainReform compare to TransCode Therapeutics?

Do institutionals and insiders have more ownership in RNAZ or PRFX?

Do analysts rate RNAZ or PRFX?

Which has stronger valuation and earnings, RNAZ or PRFX?

Is RNAZ or PRFX more profitable?

Does the media refer more to RNAZ or PRFX?

Which has more volatility & risk, RNAZ or PRFX?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PRFX vs. The Competition

PainReform Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools